Skip to content

Journal · Medical mycology · Updated 21 November 2026

Current Fungal Infection Reports

Read Current Fungal Infection Reports articles on DeepDyve. No university library needed.

Current Fungal Infection Reports covers fungal infections, with reviews on antifungal drug design and resistance, chromoblastomycosis, phaeohyphomycosis, fusariosis and antifungal prophylaxis in children. Springer Nature publishes it, and it has published since 2007. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Current Fungal Infection Reports
Journal cover

Current Fungal Infection Reports at a glance

Full title
Current Fungal Infection Reports
Abbreviation (NLM)
Curr Fungal Infect Rep
Publisher
Springer Nature
Print ISSN
1936-3761
Online ISSN (eISSN)
1936-377X
First published
2007
Access model
Hybrid (27% free to read in 2026)

Ways to access Current Fungal Infection Reports

27% of the articles Current Fungal Infection Reports published from January 1 to November 20, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 27% of Current Fungal Infection Reports articles published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Current Fungal Infection Reports. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Current Fungal Infection Reports articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Current Fungal Infection Reports’ 2025 Journal Impact Factor is 3.9, and its 5-year Impact Factor is 2.7.

3.9

Journal Impact Factor (2025)

2.7

5-year Impact Factor (2025)

9 days

Median time to first decision

Source: journal metrics on the Current Fungal Infection Reports homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Current Fungal Infection Reports research worth reading

Published February to May 2026. Summaries describe what the authors report.

  1. Open accessAntifungal resistance · Bioinformatics

    Bioinformatics in Antifungal Design: Strategies To Overcome Resistance from a Proteomic Perspective

    The authors review how bioinformatics tools such as genomic analysis, protein structural modeling, multi-omics integration and molecular docking help explain fungal resistance and guide the design of new antifungal agents, and the data, cost and validation barriers that remain.

    Romário-Silva et al. · Current Fungal Infection Reports, published online February 24, 2026 · DOI 10.1007/s12281-026-00523-4

  2. LitStreamChromoblastomycosis · Treatment

    Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies

    The authors review treatment of chromoblastomycosis, noting that posaconazole has shown the greatest potential among newer triazoles and that a protocol combining debulking, intralesional amphotericin B and oral terbinafine cured all 16 patients in a 2025 case series.

    Popovic et al. · Current Fungal Infection Reports, published online April 27, 2026 · DOI 10.1007/s12281-026-00532-3

  3. LitStreamPediatrics · Antifungal prophylaxis

    Prophylaxis of Invasive Fungal Infections in Pediatric Patients: A Narrative Review

    The authors review primary antifungal prophylaxis in high-risk children, from fluconazole in very-low-birth-weight infants to echinocandins for neonates exposed to Candida auris and children with acute myeloid leukemia, alongside environmental controls and hand hygiene.

    Castagnola et al. · Current Fungal Infection Reports, published online April 22, 2026 · DOI 10.1007/s12281-026-00529-y

  4. LitStreamPhaeohyphomycosis · Diagnosis

    Subcutaneous Phaeohyphomycosis: Clinical Manifestations and Diagnosis: a Conundrum to Solve

    The authors review subcutaneous phaeohyphomycosis, an implantation mycosis caused by melanized fungi that is often misdiagnosed, describing its varied presentations, the role of histopathology, culture, sequencing and MALDI-TOF MS in diagnosis, and treatment by surgical excision with antifungals.

    Dhawan et al. · Current Fungal Infection Reports, published online March 19, 2026 · DOI 10.1007/s12281-026-00525-2

  5. LitStreamFusariosis · Treatment

    Current Management of Fusariosis: A Systematic Review

    In a systematic review of 139 articles, the authors report that Fusarium solani species complex was the most frequently isolated group, that isolates showed high MICs to amphotericin B and azoles, and that voriconazole combined with amphotericin B was the most effective treatment.

    Madhuwantha et al. · Current Fungal Infection Reports, published online May 8, 2026 · DOI 10.1007/s12281-026-00533-2

See every Current Fungal Infection Reports article on DeepDyve

Questions about Current Fungal Infection Reports

How can I read Current Fungal Infection Reports articles without a subscription?

27% of Current Fungal Infection Reports articles published from January 1 to November 20, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Current Fungal Infection Reports articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Current Fungal Infection Reports?

Current Fungal Infection Reports’ NLM (PubMed) abbreviation is Curr Fungal Infect Rep.

What is the ISSN of Current Fungal Infection Reports?

The print ISSN is 1936-3761 and the online ISSN is 1936-377X.

What is the impact factor of Current Fungal Infection Reports?

Current Fungal Infection Reports’ Journal Impact Factor is 3.9 (2025), and its 5-year Impact Factor is 2.7, according to Springer Nature’s published metrics.

Is Current Fungal Infection Reports open access?

Current Fungal Infection Reports is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 20, 2026, 7 of 26 Current Fungal Infection Reports articles (27%) carry a Creative Commons license, per Crossref.

Current Fungal Infection Reports articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading Current Fungal Infection Reports today

One month free, then less than $2 a day. Current Fungal Infection Reports, plus millions of articles from thousands of journals.

Start free month

Like this: